Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma

European Urology

Volumn 72, Issue 4, 2017, Pages 557-564

  Pal, Sumanta K ^a   Sonpavde, Guru ^b   Agarwal, Neeraj ^c   Vogelzang, Nicholas J ^d   Srinivas, Sandy ^e   Haas, Naomi B ^f   Signoretti, Sabina ^g   McGregor, Bradley A ^g   Jones, Jeremy ^a   Lanman, Richard B ^h   Banks, Kimberly C ^h   Choueiri, Toni K ^g  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d Division of Hematology and Medical Oncology   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h Guardant Health   (United States)

Author keywords

Biomarkers; Cell free DNA; Circulating tumor DNA; Next generation sequencing; Renal cell carcinoma

Indexed keywords

ARID1A PROTEIN; AXITINIB; BEVACIZUMAB; BIOLOGICAL MARKER; CABOZANTINIB; CIRCULATING TUMOR DNA; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; NF1 PROTEIN; NIVOLUMAB; PAZOPANIB; PIK3CA PROTEIN; PROTEIN P53; SUNITINIB; TUMOR MARKER; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; ANTINEOPLASTIC AGENT; TRANSCRIPTOME;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; COHORT ANALYSIS; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENOMICS; HUMAN; HUMAN GENOME; INDEL MUTATION; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC THERAPY; AGED; BLOOD; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; FEASIBILITY STUDY; GENE EXPRESSION PROFILING; GENETICS; KIDNEY TUMOR; PATHOLOGY; RENAL CELL CARCINOMA; RETROSPECTIVE STUDY; SECONDARY; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; CIRCULATING TUMOR DNA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSCRIPTOME; TREATMENT OUTCOME;

EID: 85017454787     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2017.03.046     Document Type: Article

References (29)

1. Pal, S.K., Choueiri, T.K., Karam, J.A., Heng, D.Y., Metastatic renal cell carcinoma: contending with a sea change in therapy. Urol Oncol 33 (2015), 507–508.
2. Motzer, R.J., Hutson, T.E., Glen, H., et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16 (2015), 1473–1482.
3. Sternberg, C.N., Davis, I.D., Mardiak, J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28 (2010), 1061–1068.
4. Hudes, G., Carducci, M., Tomczak, P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007), 2271–2281.
5. Motzer, R.J., Hutson, T.E., Cella, D., et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369 (2013), 722–731.
6. Rini, B.I., Escudier, B., Tomczak, P., et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378 (2011), 1931–1939.
7. Choueiri, T.K., Escudier, B., Powles, T., et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 17 (2016), 917–927.
8. Motzer, R.J., Escudier, B., McDermott, D.F., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
9. Pal, S.K., Gorritz, M., Sherman, S.A., Liu, Z., U.S. regional practice patterns in metastatic renal cell carcinoma (mRCC) patients: a real-world retrospective analysis. ASCO Meeting Abstracts, 32, 2014, 505.
10. The Cancer Genome Atlas Research Network, Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499 (2013), 43–49.
11. Piotrowska, Z., Drapkin, B., Engelman, J.A., Nagy, R.J., Lanman, R.B., Sequist, L.V., Plasma T790M result alters treatment options in a previously T790 Wild-Type EGFR-mutant lung cancer. J Thorac Oncol 11 (2016), e95–e97.
12. Gainor, J.F., Dardaei, L., Yoda, S., et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 6 (2016), 1118–1133.
13. Lanman, R.B., Mortimer, S.A., Zill, O.A., et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PloS One, 10, 2015, e0140712.
14. Gerlinger, M., Rowan, A.J., Horswell, S., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366 (2012), 883–892.
15. Goyal, L., Saha, S.K., Liu, L.Y., et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to fgfr inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov 7 (2017), 252–263.
16. Hakimi, A.A., Pham, C.G., Hsieh, J.J., A clear picture of renal cell carcinoma. Nat Genet 45 (2013), 849–850.
17. Noon, A.P., Polanski, R., El-Fert, A.Y., et al. Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy. BJU Int 109 (2012), 1250–1257.
18. Zhao, Z., Chen, C., Lin, J., et al. Synergy between von Hippel-Lindau and P53 contributes to chemosensitivity of clear cell renal cell carcinoma. Mol Med Rep 14 (2016), 2785–2790.
19. Pal, S.K., Figlin, R.A., Reckamp, K.L., The role of targeting mammalian target of rapamycin in lung cancer. Clin Lung Cancer. 9 (2008), 340–345.
20. Lim, S.M., Park, H.S., Kim, S., et al. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. Oncotarget 7 (2016), 10547–10556.
21. Andre, F., Hurvitz, S., Fasolo, A., et al. Molecular alterations and everolimus efficacy in human epidermal growth factor receptor 2-overexpressing metastatic breast cancers: combined exploratory biomarker analysis from BOLERO-1 and BOLERO-3. J Clin Oncol 34 (2016), 2115–2124.
22. Snyder, A., Makarov, V., Merghoub, T., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371 (2014), 2189–2199.
23. Rizvi, N.A., Hellmann, M.D., Snyder, A., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
24. Choueiri, T.K., Fishman, M.N., Escudier, B., et al. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): association of biomarkers with clinical outcomes. ASCO Meeting Abstracts, 33, 2015, 4500.
25. Ho, T.H., Choueiri, T.K., Karam, J.A., et al. Correlation between findings from comprehensive genomic profiling and targeted therapy response in metastatic renal clear cell carcinoma. Eur Urol Focus 2 (2016), 204–209.
26. Kuderer, N.M., Burton, K.A., Blau, S., et al. Comparison of 2 commercially available next-generation sequencing platforms in oncology. JAMA Oncol 3 (2017), 996–998.
27. Ko, A.H., Bekaii-Saab, T., Van Ziffle, J., et al. A multicenter, open-label phase II clinical trial of combined mek plus egfr inhibition for chemotherapy-refractory advanced pancreatic adenocarcinoma. Clin Cancer Res, 22, 2016, 61.
28. Schwaederle, M., Husain, H., Fanta, P.T., et al. Use of liquid biopsies in clinical oncology: pilot experience in 168 patients. Clin Cancer Res 22 (2016), 5497–5505.
29. Schwaederle, M., Husain, H., Fanta, P.T., et al. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget 7 (2016), 9707–9717.